Company Active LTD

Company profile

Adsilico Limited

UK company 14263453, incorporated on 29 July 2022.

Home

Adsilico Limited is a UK company with status Active founded in 2022 based in Yorkshire and the Humber.

Company number
14263453
Incorporated
29 Jul 2022
Companies House status
Active

Company identity

Founded / incorporated
29 July 2022

Company number 14263453

Verify at Companies House
Legal name
ADSILICO LIMITED
Company type
Private Limited Company
Region
Yorkshire and the Humber
Registered address
NEXUS
DISCOVERY WAY
LEEDS
WEST YORKSHIRE
UNITED KINGDOM
LS2 3AA
Insolvency history
No

Corporate ownership

Updated 07 Jul 2026 09:49

1 level 1 ultimate controller
1
Company Active LTD
Adsilico Limited
CRN 14263453
2
Direct and ultimate controller Active LTD

Latest accounts

Financial period: 1 Jan 2024 to 31 Dec 2024

FILLETEDACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
10

Company events

Reference milestones and recent Companies House filing stream events.

6 events
30 Sep
2027

Accounts due

Accounts Due

Next accounts due date

11 Aug
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

04 Aug
2026

Confirmation Statement With No Updates

Confirmation-statement

CS01 | Transaction MzUzNzAyMjYxMGFkaXF6a2N4

Published 04 Aug 2026 17:41

31 Dec
2025

Accounts filed

Accounts

Last accounts made up date

28 Jul
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

29 Jul
2022

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2024
Funded years
2024, 2025
Age at first award
1 years

Projects

2025 Collaborative R&D Lead participant

EQUIVALENCE: Inclusive and representative evidence of medical device safety and efficacy based on synthetic virtual patients and in silico trials.

1 Oct 2025 to 31 Mar 2027

Awarded
£492,175
Total cost £703,107

Project EQUIVALENCE: Revolutionising Medical Device Testing with Virtual Populations Medical device testing is at a critical juncture. Traditional clinical trials, while valuable, are often limited in scope, time-consuming, and expensive. They may not adequately represent diverse populations, potentially leading to unforeseen complications when devices ar...

2024 Collaborative R&D Lead participant

TWINNING: Scalable technologies for creating virtual patient twin populations to accelerate in-silico enabled medical device innovation.

1 Apr 2024 to 31 Mar 2026

Awarded
£679,185
Total cost £970,264

**ad**silico, a spin-out from the University of Leeds (UoL), is aiming to Define, Disrupt and Dominate the in-silico trials space to accelerate medical device innovations. It will become the world's first end-to-end in-silico trials service provider. adsilico's technology for creating virtual populations (VP) of anatomy and physiology builds upon 15+ year...

Product types

Collaborative R&D